However, Opdualag remains a SoC in the first-line treatment ... It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether ...

Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS' PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by ...

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway.

Opdualag, a combination therapy of nivolumab ... and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market. Our flagship offering, the Global ...

Participants were dosed with the study drug, Opdualag, in combination with nivolumab (brand name Opdivo), a different BMS immunotherapy that’s already approved for use in this adjuvant setting.